Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams bought 33,169 shares of the business’s stock in a transaction dated Wednesday, November 18th. The shares were bought at an average price of $1.05 per share, with a total value of $34,827.45. Following the completion of the transaction, the director owned 37,026,034 shares in the company, valued at approximately $38,877,335.70. This trade represents a 0.09% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Gregg Williams also recently made the following trade(s):
- On Thursday, November 19th, Gregg Williams bought 85,265 shares of Vivani Medical stock. The shares were bought at an average cost of $1.09 per share, for a total transaction of $92,938.85.
- On Tuesday, November 17th, Gregg Williams bought 29,929 shares of Vivani Medical stock. The shares were bought at an average cost of $1.05 per share, for a total transaction of $31,425.45.
- On Monday, November 16th, Gregg Williams purchased 2,100 shares of Vivani Medical stock. The stock was bought at an average price of $1.01 per share, for a total transaction of $2,121.00.
- On Friday, November 13th, Gregg Williams purchased 48,100 shares of Vivani Medical stock. The stock was bought at an average price of $0.99 per share, for a total transaction of $47,619.00.
Vivani Medical Stock Up 4.6%
VANI stock opened at $1.14 on Friday. The company has a market cap of $102.83 million, a PE ratio of -3.56 and a beta of 2.51. The business has a 50-day simple moving average of $1.16 and a 200 day simple moving average of $1.23. Vivani Medical, Inc. has a 52 week low of $0.80 and a 52 week high of $1.66.
Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.
Analyst Upgrades and Downgrades
VANI has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Vivani Medical from a “hold” rating to a “sell” rating in a report on Sunday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vivani Medical presently has an average rating of “Hold” and a consensus price target of $3.75.
Vivani Medical Company Profile
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Featured Articles
- Five stocks we like better than Vivani Medical
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
